Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Italy Fines Apple €98.6 Million Over App Store Dominance 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
SAN DIEGO, Aug. 02, 2017 -- TearLab Corporation (NASDAQ:TEAR) (TSX:TLB) (the “Company”) will announce its second quarter 2017 financial results after market close on Monday, August 14, 2017.
TearLab’s Chief Executive Officer, Seph Jensen and Chief Financial Officer, Wes Brazell, will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period.
Second Quarter 2017 Results Conference Call Details:
Date: Monday, August 14, 2017
Time: 4:30 p.m. ET
Live Call: 877-303-1593 (Pass Code: 61973019)
Replay: 855-859-2056 (Pass Code: 61973019)
The call will also be broadcast live and archived on the Company's website at www.tearlab.com under the "Webcasts" tab in the Investor's section.
About TearLab Corporation
TearLab Corporation (www.tearlab.com) develops and markets lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by objectively and quantitatively testing for disease markers in tears at the point-of-care. The TearLab Osmolarity Test, for diagnosing Dry Eye Disease, is the first assay developed for the award-winning TearLab Osmolarity System. TearLab Corporation's common shares trade on the NASDAQ Capital Market under the symbol 'TEAR' and on the Toronto Stock Exchange under the symbol 'TLB'.
Investor Contact: The Ruth Group Lee Roth Tel: 646-536-7012 [email protected]
